Canagliflozin reduces the risk of CKD progression in type 2 diabetes with nephropathy - main results of the CREDENCE study
Abstract
Diabetic kidney disease in patients with type 2 diabetes is the most frequent cause of end-stage renal disease. Inhibition of the renin-angiotensin system in patients with type 2 diabetes slows down but does not halt the progression of chronic kidney disease.
In the CREDENCE study canagliflozin, inhibitor of the sodium-glucose transporter 2 (SGLT2) in the proximal tubule of the kidney, significantly decreased the risk of the composite primary outcome (doubling of serum creatinine, end-stage renal disease and cardiovascular mortality) and renal-specific secondary outcome (doubling of serum creatinine or end-stage renal disease). SGLT2 inhibitors with demonstrated renoprotective action should the treatment of choice in patients with type 2 diabetes and chronic kidney disease.
